A New Era in the Prevention and Management of Cytomegalovirus (CMV) Infection in Transplant Recipients: Assessing the Evidence in Real-World Applications

A continuing medical education activity provided by NAMCP and AAMCN

A New Era in the Prevention and Management of CMV Infection is a two-part webinar series

This is Part 2 of the series focusing on management of Cytomegalovirus (CMV) Infection

This activity is an archive from the webinar held July 28, 2021

This activity is valid from September 1, 2021 – September 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck

Description:
Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT. Antiviral prophylaxis is effective against direct and indirect effects of CMV infection. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Novel antiviral therapies with different mechanisms of action have recently become available giving healthcare professionals new options in the management of this infection. This program will take a look at those advances and provide up to date strategies for the management of CMV infection.

This webinar series on the evolving role of novel therapies in CMV infection management will take a close look at recent guideline updates, clinical data, and strategies for the prevention and management of CMV.

Upon completion of this activity, participants will be able to:

  • Describe patient populations and procedures associated with the greatest risk for negative outcomes due to CMV infection or reactivation

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients

  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients

  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation

  • Review recent guideline statements and expert recommendations for CMV infection management, prevention, and follow-up care

     

Faculty: Roy F Chemaly, MD, MPH, FIDSA, FACP

Disclosure:

Dr. Chemaly has received research/grant support from Merck, Chimerix, Takeda/Shire, Oxford Immunotec, Viracor, and Novartis. He serves on the as a consultant, speaker, and on an advisory board for Merck, Chimerix, Takeda/Shire, Oxford Immunotec, and Clinigen.
Planning Committee Disclosures: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue